Human mesenchymal stem cells for the management of systemic sclerosis. Systematic review |
| |
| Authors: | Carlos-Hugo Escobar-Soto Rossana Mejia-Romero Natalia Aguilera Juan Pablo Alzate-Granados Claudia Mendoza-Pinto Pamela Munguía-Realpozo Socorro Méndez-Martínez Mario García-Carrasco Adriana Rojas-Villarraga |
| |
| Affiliation: | 1. Systemic Autoimmune Diseases Research Unit CIBIOR, Hospital de Especialidades, UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico;2. Rheumatology Department, School of Medicine, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico;3. Internal Medicine Service, Hospital General de Zona N°1, Instituto Mexicano del Seguro Social, Pachuca, Hidalgo, Mexico;4. Clinical Research Department, Regional Hospital, Instituto de Seguridad y Servicios Sociales de los Trabajadores del Estado, Puebla, Mexico;5. Department of Biomedicine, School of Medicine, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico;6. Research in Health Unit, UMAE, Instituto Mexicano del Seguro Social, Puebla, Mexico;7. Research in Health Coordination, Instituto Mexicano del Seguro Social, Puebla, Mexico;1. Systemic Autoimmune Diseases Research Unit, UMAE Manuel Ávila Camacho-CIBIOR Instituto Mexicano del Seguro Social, Puebla, Mexico;2. Department of Rheumatology, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico;3. Physiotherapy Program, Medical School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico;4. Division of Health Research UMAE Manuel Ávila Camacho, Instituto Mexicano del Seguro Social Puebla, Puebla, Mexico;5. Department of Psychology, Medical School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico;6. Medical School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico;7. Puebla Research Coordination, High-Specialty Medical Unit, Specialty Hospital of Puebla, Instituto Mexicano del Seguro Social, Puebla, Mexico;1. Department of Internal Medicine, Division of Rheumatology, Scleroderma Program, University of Michigan, Ann Arbor, Michigan, USA;2. Academic Respiratory Unit, School of Clinical Sciences, University of Bristol, UK; Bristol Interstitial Lung Disease Service, North Bristol NHS Trust, Southmead, Bristol, UK;3. Department of Internal Medicine, Division of Pulmonology, Royal Brompton Hospital and National Heart and Lung Institute; London, UK;4. HCor Research Institute, Hospital do Coração, São Paulo, Brazil; Pulmonary Division, Heart Institute (InCor), University of Sao Paulo Medical School, São Paulo, Brazil;5. Department of Medicine, Division of Pulmonary and Critical Care Medicine, David Geffen School of Medicine at UCLA, Los Angeles, California, USA;6. Division of Immunology/Rheumatology, Stanford University, Palo Alto, California, USA;7. Scleroderma Research Consultants, Aiken, South Carolina, USA;8. Rheumatology Unit, Royal Adelaide Hospital and Professor Discipline of Medicine, University of Adelaide, Adelaide, AUS;9. Department of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Hospital, Denver, Colorado, USA;10. Department of Medicine, Division of Rheumatology, Inflammation, and Immunity, Brigham and Women''s Hospital, Harvard Medical School, Boston, MA, USA;11. Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Brigham and Women''s Hospital, Harvard Medical School, Boston, MA, USA;12. From Clinical Development and Medical Affairs, Specialty Care Boehringer Ingelheim Pharmaceuticals, Inc. USA;13. Department of Internal Medicine, Division of Rheumatology, Mayo Clinic, Rochester, Minnesota, USA;14. Division of Rheumatology and Clinical Immunology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania, USA;15. Department of Internal Medicine, Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, Minnesota, USA;p. Faculty of Medicine, University of Ottawa, Ottawa, CA;q. Institute for Work & Health and Institute for Health Policy Management and Evaluation, University of Toronto, Toronto, CA;r. Musculoskeletal Statistics Unit, the Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, & Research Unit of Rheumatology, Department of Clinical Research, University of Southern Denmark, Odense University Hospital, Odense, Denmark;s. Taubman Health Sciences Library, University of Michigan, Ann Arbor, MI, USA |
| |
| Abstract: | ![]()
IntroductionSistemic Sclerosis (SSc) is a heterogeneous autoimmune disease with a high rate of progression and therapeutic failure, and treatment is a challenge, new therapeutic proposals being needed, being mesenchymal stem cells (MSCs) considered as alternative therapy for SSc for its immunomodulatory capacity. We evaluated the efficacy and safety of human MSC (hMSC) in patients with SSc through a systematic literature review (SLR).MethodsSLR (PRISMA guideline) on MEDLINE/OVID, LILACS, EMBASE, and Cochrane/OVID bases (until July 2020, without limits). All types of clinical studies were considered: patients ≥18 years old with SSc and treatment with hMSC. Exclusion criteria: animal models, autologous/allogenic hematopoietic stem cell transplants, narrative reviews, letters to the editor. MeSH and “Key word” terms were used. The level of evidence and the quality rating were rated [Joanna Briggs Institute (JBI) lists]. Registration in PROSPERO repository (ID CRD42020185245) The Synthesis Without Meta-analysis (SWiM) guideline was followed.ResultsWe initially identified 508 articles, of which 11 were finally included (8 case series and 3 case reports). The 11 articles included 101 patients (85 female, age range 18–75 years). The level of evidence was mostly 4 (JBI); the quality of evidence was met (≥50% of JBI items). SWiM showed that vascular skin involvement (digital ulcers, necrosis, and gangrene) and associated pain were the predominant outcomes, while improvements were found in almost all cases. One patient died in the first month, and the frequency of complications was low. Expanded hMSCs were used in 24 patients and other cell sources in the remaining patients.ConclusionThere is too little reported data to reach definite conclusions about the use of hMSC in SSc. Further studies with better epidemiological designs are needed to evaluate the benefit of hMSCs in SSc patients. |
| |
| Keywords: | |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
